Compare AbbVie Inc (ABBV) vs McKesson Corporation (MCK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs McKesson Corporation — how do they compare? AbbVie Inc trades at $253.85 (market cap $449.91B), while McKesson Corporation trades at $817.95 (market cap $94.52B). The key difference: AbbVie Inc is far larger — about 4.8× McKesson Corporation's market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | MCK | |
|---|---|---|
Market Cap | $449.91B | $94.52B |
Sector | Health | Health |
52-Week High | $261.07 | $995.69 |
52-Week Low | $184.85 | $659.01 |
Enterprise Value | $513.38B | $99.16B |
Dividend Yield | 2.72% | 0.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.
The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.
McKesson (MCK) trades at $807.33, up 2.67% with strong bullish momentum. The stock shows robust fundamentals with consistent earnings beats and revenue growth from $309B to $359B in 2025. Technical indicators signal bullish momentum with price above key support levels. Recent news highlights McKesson's growth in specialty pharma and oncology services, supported by positive analyst sentiment.
Outlook remains positive with 80% analyst buy ratings and $932.83 consensus price target, offering 15% upside. Risks include policy pressures and margin compression, but diversified portfolio and investment-grade rating provide stability. Earnings momentum and strategic investments position MCK for continued growth in healthcare distribution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
